Table 1.
Baseline demographics and clinical characteristics
| Control group† (n = 154) | Study treatment group‡ (n = 151) | |
|---|---|---|
| Gender, n (%) | ||
| Female | 67 (43.5) | 65 (43.0) |
| Male | 87 (56.5) | 86 (57.0) |
| Age, n (%) | ||
| <55 years | 22 (14.3) | 24 (15.9) |
| ≥55 years | 132 (85.7) | 127 (84.1) |
| Mean (min–max) | 64.0 (23–88) | 64.1 (34–85) |
| Alcohol consumption within 180 days of enrollment, n (%) | ||
| Yes | 68 (44.2) | 70 (46.4) |
| No | 80 (51.9) | 77 (51.0) |
| Unknown | 6 (3.9) | 4 (2.6) |
| Chemotherapy regimen, n (%) | ||
| Oxaliplatin-based | 112 (72.7) | 110 (72.8) |
| Irinotecan-based | 20 (13.0) | 21 (13.9) |
| Carboplatin-based | 19 (12.3) | 18 (11.9) |
| Other | 3 (1.9) | 2 (1.3) |
†Control group: Palonosetron day 1+ dexamethasone days 1–3. ‡Study treatment group: Palonosetron day 1+ dexamethasone day 1.